Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)

Autor:	A. Barnadas Molins, C. González Blanco, D. Castillo Villegas, P. Gomila Pons, I. Gich Saladich, M. Majem Tarruella, C. Facundo Molas, S.D. Camacho Arellano, M. Andrés Granyo, S. Moron Asensio, M. Riudavets Melia, A. Barba Joaquín, I. Gabriela Sullivan, G. Anguera Palacios, C. Molto Valiente, E. Garcia Planella, L.P. del Carpio
Rok vydání:	2018
Předmět:	Oncology medicine.medical_specialty Immune system business.industry Internal medicine Immune checkpoint inhibitors medicine In patient Hematology Adverse effect business
Zdroj:	Annals of Oncology. 29:viii509
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::32770e23806118081f2e8b6e4f61701e https://doi.org/10.1093/annonc/mdy292.031 Zobrazit plný text záznamu